PP
TPST icon

Paloma Partners’s Tempest Therapeutics TPST Stock Holding History

Paloma Partners’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-381
Closed -$131K – 2459
2020
Q2 		$131K Buy
+381
New +$152K ﹤0.01% 1840
2017
Q3 		– Sell
-39
Closed -$180K – 2429
2017
Q2 		$180K Buy
+39
New +$165K ﹤0.01% 2021
2017
Q1 		– Sell
-6
Closed -$25K – 2239
2016
Q4 		$25K Buy
+6
New +$74.7K ﹤0.01% 1940

Other funds holding TPST

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

Paloma Partners's TPST Position: Q3 2020 in Review

Paloma Partners sold out of Tempest Therapeutics (TPST) in Q3 2020, closing a stake of 381 shares — an estimated $131K sold.

Paloma Partners first reported a position in TPST in Q4 2016 and held it in 3 quarters. The position peaked at $180K in Q2 2017. 42 funds tracked by Wall St. Rank hold TPST as of Q3 2020.

  • Paloma Partners reported no remaining Tempest Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Paloma Partners sold 381 Tempest Therapeutics shares in Q3 2020, an estimated $131K.
  • Paloma Partners first reported a position in Tempest Therapeutics in Q4 2016 and held it in 3 quarters.
  • Paloma Partners's Tempest Therapeutics position peaked at $180K in Q2 2017.
  • 42 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2020.

Based on Paloma Partners's 13F filing for Q3 2020, filed 16 Nov 2020.